U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07737795) titled 'Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer' on July 27.
Brief Summary: The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Endometrial Cancer
Intervention:
DRUG: OK-1 & Paclitaxel
OK-1 capsules will be administered orally at 3.5-4.5 mg/kg twice a day during a 21-day cycle (3 weeks on, one week off in a 28-day cycle)
Other Names:
* NSC 726189
Paclitaxel ...